BI's Pradaxa antidote gets Breakthrough label

Share this article:

Boehringer Ingelheim announced today that its experimental antidote, designed to stop the bleeding for blood thinner agent Pradaxa, has received a Breakthrough Therapy designation from the FDA—making it the first antidote of its kind for this new class of anticoagulants.

BI recently settled 4,000 Pradaxa lawsuits for $650 million. The lawsuits centered on claims that there was no antidote to prevent bleeding-related deaths. FDA stated in November 2012, however, that the bleeding rates associated with Pradaxa were no higher than with warfarin.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.